Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, and Hepatitis Viruses Studies and Epidemiology.
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
Safety of direct-acting antivirals for Hepatitis C infection and direct oral anticoagulants co-administration: an Italian multicentric study
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Artificial Intelligence and liver: Opportunities and barriers
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study
Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)
The application of artificial intelligence in hepatology: A systematic review
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
The changing scenario of hepatocellular carcinoma in Italy: an update
Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis
Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma